查看購物車
  • Simplified Chinese
  • English
封面
市場調查報告書
商品編碼
1871211

精準診斷及醫療市場機會、成長促進因素、產業趨勢分析及預測（2025-2034年）

Precision Diagnostics and Medicine Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025 - 2034
出版日期: | 出版商: Global Market Insights Inc. | 英文 146 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

2024 年全球精準診斷和醫療市場價值為 1,226 億美元，預計到 2034 年將以 13.5% 的複合年成長率成長至 4,484 億美元。

精準診斷與醫療市場 - IMG1

精準醫療正在變革醫療保健，它將治療模式從標準化轉向基於個人基因譜、生活方式和環境的高度客製化方案。這種方法著重於個人化策略而非通用方案，進而改善多種疾病的治療效果。數據驅動診斷技術的快速發展，以及對標靶治療日益成長的需求，持續推動市場的發展。多組學平台的整合正在加速創新，為臨床醫生和研究人員提供對複雜生物系統的深入洞察。隨著精準療法的普及和監管框架的完善，全球範圍內的精準醫療應用有望進一步擴大。醫療機構和生物製藥公司正在攜手合作，支持臨床整合，而數位技術和伴隨診斷則進一步強化了個人化治療方案。

市場範圍
起始年份 2024
預測年份 2025-2034
起始值 1226億美元
預測值 4484億美元
複合年成長率 13.5%

2024年，治療領域市佔率達到58.7%，預計到2034年將以13.3%的複合年成長率成長。專注於設計針對個別患者情況的客製化療法是推動這一成長的主要動力。細胞療法、基因療法和免疫標靶藥物的進步正在重塑治療方案，尤其是在複雜或罕見疾病方面。高昂的研發成本和高昂的藥品定價仍然是該領域價值成長的主要驅動力。

預計到2034年，基因組學市場規模將達到1,084億美元。基因組技術在理解特定基因變異如何影響疾病進展和治療反應方面發揮著至關重要的作用。諸如新一代定序和全基因組分析等技術能夠精確識別可標靶的突變。這顯著提升了基因組學在藥物研發和個人化治療策略中的作用，並鞏固了其在臨床診斷和研究應用中的重要性。

2024年，北美精準診斷和醫療市場佔43.5%的佔有率。該地區憑藉強大的醫療基礎設施、高額的研發投入以及眾多頂尖製藥和生物技術公司，繼續保持領先地位。有利的監管框架和大量的政府支出進一步推動了個人化醫療的創新。此外，伴隨診斷的廣泛應用和先進的基因組檢測技術也鞏固了該地區的市場地位。

引領精準診斷和醫療市場發展的領導企業包括Illumina、諾華、Cepheid（丹納赫公司）、Qiagen、武田藥品工業株式會社、輝瑞、羅氏、美國實驗室控股公司（Labcorp）、賽默飛世爾科技、百時美施貴寶公司、葛蘭素史克、安捷倫科技、阿斯潘特、安捷倫科技、阿斯特西古、安捷蘭素史克、安捷倫科技、阿斯特西古、 Diagnostics、生物梅里埃、Natera、禮來公司、雅培和艾伯維。為了擴大市場佔有率，精準診斷和醫療市場的關鍵企業正致力於策略合作、夥伴關係和收購，以增強其產品線並實現技術能力的多元化。各公司正大力投資多組學平台、人工智慧驅動的資料分析和先進的基因組解決方案，以提高診斷的準確性和治療的個人化。透過數據驅動模型提高臨床試驗的精確度並加快法規核准也是其核心策略。

目錄

第1章：方法論與範圍

第2章：執行概要

第3章：行業洞察

  • 產業生態系分析
  • 產業影響因素
    • 成長促進因素
      • 基因組學和生物技術的進步
      • 慢性病和遺傳性疾病盛行率不斷上升
      • 增加政府措施和資金投入
      • 伴隨診斷的普及應用
    • 產業陷阱與挑戰
      • 個人化治療和診斷成本高昂
      • 有限的報銷政策
      • 複雜的調控通路
    • 市場機遇
      • 迅速擴展到非腫瘤領域
      • 新興市場的成長
  • 成長潛力分析
  • 監管環境
    • 北美洲
      • 美國
      • 加拿大
    • 歐洲
    • 亞太地區
    • 拉丁美洲
    • 中東和非洲
  • 技術格局
    • 當前趨勢
    • 新興技術
  • 管道分析
  • 未來市場趨勢
  • 波特的分析
  • PESTEL 分析

第4章：競爭格局

  • 介紹
  • 公司市佔率分析
    • 全球的
    • 北美洲
    • 歐洲
    • 亞太地區
  • 公司矩陣分析
  • 主要市場參與者的競爭分析
  • 競爭定位矩陣
  • 關鍵進展
    • 併購
    • 夥伴關係與合作
    • 新產品發布
    • 擴張計劃

第5章：市場估算與預測：依產品類型分類，2021-2034年

  • 主要趨勢
  • 診斷
    • 基因檢測
    • 基於生物標記的檢測
    • 神秘測試
    • 其他診斷測試
  • 療法
    • 抑制劑類藥物
    • 單株抗體
    • 細胞和基因治療
    • 抗病毒藥物和抗逆轉錄病毒藥物
    • 其他療法

第6章：市場估算與預測：依指示劑分類，2021-2034年

  • 主要趨勢
  • 腫瘤學
  • 神經病學
  • 傳染病
  • 免疫學
  • 罕見疾病和遺傳性疾病
  • 心臟病學
  • 其他跡象

第7章：市場估計與預測：依技術分類，2021-2034年

  • 主要趨勢
  • 基因組學
  • 生物資訊學
  • 巨量資料分析
  • 生物標記檢測
  • 高通量篩選
  • 其他技術

第8章：市場估算與預測：依最終用途分類，2021-2034年

  • 主要趨勢
  • 醫院和診所
  • 診斷實驗室
  • 其他最終用途

第9章：市場估計與預測：依地區分類，2021-2034年

  • 主要趨勢
  • 北美洲
    • 美國
    • 加拿大
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 西班牙
    • 義大利
    • 荷蘭
  • 亞太地區
    • 中國
    • 印度
    • 日本
    • 澳洲
    • 韓國
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 阿根廷
  • 中東和非洲
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國

第10章：公司簡介

  • Agilent Technologies
  • Abbott
  • AbbVie
  • AstraZeneca
  • bioMerieux
  • Bristol-Myers Squibb Company
  • Cepheid (Danaher Corporation)
  • Eli Lilly & Company
  • F. Hoffmann-La Roche
  • GlaxoSmithKline
  • Illumina
  • Laboratory Corporation of America Holdings (Labcorp)
  • Myriad Genetics
  • Novartis
  • Natera
  • Pfizer
  • Qiagen
  • Quest Diagnostics
  • Takeda Pharmaceutical Company Limited
  • Thermo Fisher Scientific
簡介目錄
Product Code: 14971

The Global Precision Diagnostics and Medicine Market was valued at USD 122.6 Billion in 2024 and is estimated to grow at a CAGR of 13.5% to reach USD 448.4 Billion by 2034.

Precision Diagnostics and Medicine Market - IMG1

Precision medicine is transforming healthcare by shifting from standardized treatments to highly tailored approaches based on an individual's genetic profile, lifestyle, and environment. This approach focuses on personalized strategies rather than generalized protocols, driving improved outcomes across various diseases. Rapid advancements in data-driven diagnostics, coupled with growing demand for targeted treatments, continue to shape the evolution of the market. Integration of multi-omics platforms is accelerating innovation, providing clinicians and researchers with detailed insights into complex biological systems. As precision therapies become more accessible and regulatory frameworks evolve to support quicker approval of innovative treatments, global adoption is poised to increase. Healthcare providers and biopharma companies are aligning efforts to support clinical integration, while digital technologies and companion diagnostics strengthen personalized treatment plans.

Market Scope
Start Year2024
Forecast Year2025-2034
Start Value$122.6 Billion
Forecast Value$448.4 Billion
CAGR13.5%

In 2024, the therapeutics segment held 58.7% share and is forecasted to grow at a CAGR of 13.3% through 2034. The focus on designing therapies tailored to individual patient profiles is fueling this growth. Advances in cellular therapies, gene-based solutions, and immune-targeted drugs are reshaping treatment protocols, especially for complex or rare diseases. High development costs and premium drug pricing continue to drive value across this segment.

The genomics segment is anticipated to hit USD 108.4 Billion by 2034. Genomic technologies play a critical role in understanding how specific genetic variations affect disease progression and treatment response. Techniques such as next-generation sequencing and full genome analysis allow for precise identification of actionable mutations. This has significantly elevated the role of genomics in both drug development and personalized therapeutic strategies, reinforcing its significance in clinical diagnostics and research applications.

North America Precision Diagnostics and Medicine Market held 43.5% share in 2024. The region continues to lead the way, supported by robust healthcare infrastructure, high R&D investment, and the presence of top-tier pharmaceutical and biotech companies. Favorable regulatory frameworks and substantial government spending further support innovation in personalized healthcare. Additionally, the widespread availability of companion diagnostics and the presence of sophisticated genomic testing technologies contribute to the region's strong market position.

Leading companies shaping the Precision Diagnostics and Medicine Market include Illumina, Novartis, Cepheid (Danaher Corporation), Qiagen, Takeda Pharmaceutical Company Limited, Pfizer, F. Hoffmann-La Roche, Laboratory Corporation of America Holdings (Labcorp), Thermo Fisher Scientific, Bristol-Myers Squibb Company, GlaxoSmithKline, Agilent Technologies, Myriad Genetics, AstraZeneca, Quest Diagnostics, bioMerieux, Natera, Eli Lilly & Company, Abbott, and AbbVie. To expand their footprint, key players in the Precision Diagnostics and Medicine Market are focusing on strategic collaborations, partnerships, and acquisitions to enhance their product pipelines and diversify technological capabilities. Companies are investing heavily in multi-omics platforms, AI-powered data analytics, and advanced genomic solutions to improve the accuracy of diagnostics and personalization of treatments. Enhancing clinical trial precision and speeding regulatory approvals through data-driven models are also core strategies.

Table of Contents

Chapter 1 Methodology and Scope

  • 1.1 Market scope and definition
  • 1.2 Research design
    • 1.2.1 Research approach
    • 1.2.2 Data collection methods
  • 1.3 Data mining sources
    • 1.3.1 Global
    • 1.3.2 Regional/Country
  • 1.4 Base estimates and calculations
    • 1.4.1 Base year calculation
    • 1.4.2 Key trends for market estimation
  • 1.5 Primary research and validation
    • 1.5.1 Primary sources
  • 1.6 Forecast model
  • 1.7 Research assumptions and limitations

Chapter 2 Executive Summary

  • 2.1 Industry 360° synopsis
  • 2.2 Key market trends
    • 2.2.1 Regional trends
    • 2.2.2 Product type trends
    • 2.2.3 Indication trends
    • 2.2.4 Technology trends
    • 2.2.5 End use trends
  • 2.3 CXO perspectives: Strategic imperatives
    • 2.3.1 Key decision points for industry executives
    • 2.3.2 Critical success factors for market players
  • 2.4 Future outlook and strategic recommendations

Chapter 3 Industry Insights

  • 3.1 Industry ecosystem analysis
  • 3.2 Industry impact forces
    • 3.2.1 Growth drivers
      • 3.2.1.1 Advancements in genomics and biotechnology
      • 3.2.1.2 Rising prevalence of chronic and genetic diseases
      • 3.2.1.3 Increasing government initiatives and funding
      • 3.2.1.4 Increased adoption of companion diagnostics
    • 3.2.2 Industry pitfalls and challenges
      • 3.2.2.1 High cost of personalized therapies and diagnostics
      • 3.2.2.2 Limited reimbursement policies
      • 3.2.2.3 Complex regulatory pathways
    • 3.2.3 Market opportunities
      • 3.2.3.1 Rapid expansion into non-oncology fields
      • 3.2.3.2 Growth in emerging markets
  • 3.3 Growth potential analysis
  • 3.4 Regulatory landscape
    • 3.4.1 North America
      • 3.4.1.1 U.S.
      • 3.4.1.2 Canada
    • 3.4.2 Europe
    • 3.4.3 Asia Pacific
    • 3.4.4 Latin America
    • 3.4.5 Middle East and Africa
  • 3.5 Technology landscape
    • 3.5.1 Current trends
    • 3.5.2 Emerging technologies
  • 3.6 Pipeline analysis
  • 3.7 Future market trends
  • 3.8 Porter's analysis
  • 3.9 PESTEL analysis

Chapter 4 Competitive Landscape, 2024

  • 4.1 Introduction
  • 4.2 Company market share analysis
    • 4.2.1 Global
    • 4.2.2 North America
    • 4.2.3 Europe
    • 4.2.4 Asia Pacific
  • 4.3 Company matrix analysis
  • 4.4 Competitive analysis of major market players
  • 4.5 Competitive positioning matrix
  • 4.6 Key developments
    • 4.6.1 Merger and acquisition
    • 4.6.2 Partnership and collaboration
    • 4.6.3 New product launches
    • 4.6.4 Expansion plans

Chapter 5 Market Estimates and Forecast, By Product Type, 2021 - 2034 ($ Mn)

  • 5.1 Key trends
  • 5.2 Diagnostics
    • 5.2.1 Genetic tests
    • 5.2.2 Biomarker-based tests
    • 5.2.3 Esoteric tests
    • 5.2.4 Other diagnostic tests
  • 5.3 Therapeutics
    • 5.3.1 Inhibitor drugs
    • 5.3.2 Monoclonal antibodies
    • 5.3.3 Cell and gene therapy
    • 5.3.4 Antiviral and anti-retroviral drugs
    • 5.3.5 Other therapeutics

Chapter 6 Market Estimates and Forecast, By Indication, 2021 - 2034 ($ Mn)

  • 6.1 Key trends
  • 6.2 Oncology
  • 6.3 Neurology
  • 6.4 Infectious diseases
  • 6.5 Immunology
  • 6.6 Rare and genetic disorders
  • 6.7 Cardiology
  • 6.8 Other indications

Chapter 7 Market Estimates and Forecast, By Technology, 2021 - 2034 ($ Mn)

  • 7.1 Key trends
  • 7.2 Genomics
  • 7.3 Bioinformatics
  • 7.4 Big data analytics
  • 7.5 Biomarker detection
  • 7.6 High-throughput screening
  • 7.7 Other technologies

Chapter 8 Market Estimates and Forecast, By End Use, 2021 - 2034 ($ Mn)

  • 8.1 Key trends
  • 8.2 Hospitals and clinics
  • 8.3 Diagnostic laboratories
  • 8.4 Other end use

Chapter 9 Market Estimates and Forecast, By Region, 2021 - 2034 ($ Mn)

  • 9.1 Key trends
  • 9.2 North America
    • 9.2.1 U.S.
    • 9.2.2 Canada
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 UK
    • 9.3.3 France
    • 9.3.4 Spain
    • 9.3.5 Italy
    • 9.3.6 Netherlands
  • 9.4 Asia Pacific
    • 9.4.1 China
    • 9.4.2 India
    • 9.4.3 Japan
    • 9.4.4 Australia
    • 9.4.5 South Korea
  • 9.5 Latin America
    • 9.5.1 Brazil
    • 9.5.2 Mexico
    • 9.5.3 Argentina
  • 9.6 Middle East and Africa
    • 9.6.1 South Africa
    • 9.6.2 Saudi Arabia
    • 9.6.3 UAE

Chapter 10 Company Profiles

  • 10.1 Agilent Technologies
  • 10.2 Abbott
  • 10.3 AbbVie
  • 10.4 AstraZeneca
  • 10.5 bioMerieux
  • 10.6 Bristol-Myers Squibb Company
  • 10.7 Cepheid (Danaher Corporation)
  • 10.8 Eli Lilly & Company
  • 10.9 F. Hoffmann-La Roche
  • 10.10 GlaxoSmithKline
  • 10.11 Illumina
  • 10.12 Laboratory Corporation of America Holdings (Labcorp)
  • 10.13 Myriad Genetics
  • 10.14 Novartis
  • 10.15 Natera
  • 10.16 Pfizer
  • 10.17 Qiagen
  • 10.18 Quest Diagnostics
  • 10.19 Takeda Pharmaceutical Company Limited
  • 10.20 Thermo Fisher Scientific